Markets

Puma Biotechnology (PBYI) Looks Good: Stock Rises 10.4%

Puma Biotechnology, Inc.PBYI was a big mover last session, as the company saw its shares rise over 10% on the day. The move came on the company's announcement of interim results from the ongoing phase II study on breast cancer drug PB272 on Friday. This led to solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 9.3% in the last one month.

The company has seen no estimate revisions in the past 30 days and the Zacks Consensus Estimate has also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Puma Biotechnology currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked biotechnology stock is Anika Therapeutics Inc. ANIK , sporting a Zacks Rank #1 (Strong Buy).

Is PBYI going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK PBYI

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More